SLCO2A1 encodes a prostaglandin transporter (PGT) that mediates cellular uptake of prostaglandins (primarily PGE2, PGF2α, PGD2) and thromboxanes across the plasma membrane 1. The transporter uses lactate as a counter-substrate to facilitate prostaglandin influx and efflux through secondary active transport 1. Recent cryo-EM structures reveal that PGE2 binds in the central cavity through specific interactions with conserved residues, establishing the structural basis for substrate recognition 2. SLCO2A1 regulates prostaglandin signaling by clearing these lipid mediators from circulation through cellular uptake, enabling cytoplasmic oxidation and signal termination 1. In epithelial tissues, apically expressed SLCO2A1 facilitates transcellular transport, with particularly important roles in renal sodium balance and reproductive function 1. Beyond prostaglandin transport, SLCO2A1 functions as a core component of the Maxi-Cl anion channel, regulating ATP and glutamate release 3. Loss-of-function mutations cause two autosomal recessive disorders: primary hypertrophic osteoarthropathy (PHO), characterized by elevated PGE2 levels leading to clubbing and periostosis 4, and chr3 enteropathy associated with SLCO2A1 (CEAS), marked by small intestinal ulceration due to impaired prostaglandin clearance and subsequent barrier dysfunction 5. SLCO2A1 represents a therapeutic target for conditions including diabetic foot ulcers and fever 1.